In this study, we report the amelioration of parkinsonian symptoms in rat Parkinson's disease (PD) models, as a result of the expression of glutamate decarboxylase (GAD) 65 with a modified cytomegalovirus (CMV) promoter. The transfer of the gene for gamma-amino butryic acid (GAD), the rate-limiting enzyme in gama-amino butrylic acid (GABA) production, has been investigated as a means to increase inhibitory synaptic activity. Electrophysiological evidence suggests that the transfer of the GAD65 gene to the subthalamic nucleus (STN) can change the excitatory output of this nucleus to inhibitory output. Our in vitro results also demonstrated higher GAD65 expression in cells transfected with the JDK promoter, as compared to cells transfected with the CMV promoter. Also, a rat PD model in which recombinant adeno-associated virus-2 (rAAV2)-JDK-GAD65 was delivered into the STN exhibited significant behavioral improvements, as compared to the saline-injected group. Interestingly, we observed that these behavioral improvements were more obvious in rat PD models in which rAAV2-JDK-GAD65 was injected into the STN than in rat PD models in which rAAV2-CMV-GAD65 was injected into the STN. Moreover, according to electrophysiological data, the rAAV2-JDK-GAD65-injected group exhibited more constant improvements in firing rates than did the rAAV2-CMV-GAD65-injected group. These data indicate that the JDK promoter, when coupled with GAD65 expression, is more effective with regard to parkinsonian symptoms than is the CMV promoter.
Introduction
The mammalian central nervous system (CNS) comprises both excitatory and inhibitory neurons, which are organized into networks. Two neurotransmitters, glutamate and gamma-amino butryric acid (GABA), are the principal vehicles for excitation and inhibition, respectively, in Parkinson's disease (PD). They originate from the degeneration of dopaminergic neurons in the substantia nigra (SN) pars compacta, resulting in reduced functioning of inhibitory nigrostriatal projections. 1 The circuitry of the basal ganglia indicates that overactivation of the subthalamic nucleus (STN) may also result from this decreased inhibition. These excitatory neurons serve to increase the firing rates of neurons in the globus pallidus pars interna and SN pars reticulata (SNpr), which, in turn, inhibit brainstem and thalamic projections to downstream motor pathways, thereby inhibiting the initiation of voluntary movement. 1, 2 Recently, a gene transfer strategy predicated on this approach has been developed. 3 The transduction of neurons in the ipsilateral STN with the infusion of an adenoassociated vector coding for glutamic acid decarboxylase (GAD), the rate-limiting enzyme for GABA synthesis, resulted in the synthesis and activity-dependent release of GABA from the STN nerve terminals. Electrophysiological recordings obtained from the brains of GAD-treated 6-hydroxydopamine (6-OHDA)-lesioned rats confirmed an increase in inhibitory responses in these animals.
Of the variety of available delivery systems, viral vectors have been the most widely used for gene transfer to the CNS. Adeno-associated virus-2 (AAV-2) vectors can effect transgene expression in brain neurons with a high degree of efficiency, and tend not to induce overt pathological responses. 4, 5 AAV-2 vectors have also proven to be able to transduce postmitotic cells, including neurons, astrocytes, and oligodendrocytes, 6, 7 which constitute the primary target cells in CNS disorders. They also provide sustained, long-term gene expression, which is required for the treatment of chronic diseases. 8 Although recombinant AAV (rAAV) is limited to a transgene size of 4.9 kb, this is large enough to contain the cDNAs for neurotrophic factor genes, suicide genes, and lysosomal enzyme genes. 9 Therefore, AAV vectors tend to be excellent tools for the gene therapy of neurological diseases.
In this study, we used rAAV to transduce neurons in the STN, and compared the effectiveness of the cytomegalovirus (CMV) promoter with that of the JDK promoter (a modified CMV promoter), with regard to GAD65 expression, as well as the efficacy of synthesis of GABA, the major inhibitory neurotransmitter in the brain. We evaluated the effects of the transduction of the GAD65 gene into the STN on behavior in a rat parkinsonian model, using apomorphine-induced rotational behavior and forepaw-adjusting techniques. Furthermore, we attempted to characterize the alteration of neuronal activities after the introduction of GAD65, by evaluating electrophysiological changes.
Results

Recombinant AAV expresses functional GAD65 gene in vitro
We constructed rAAV vectors, which expressed either bgalactosidase (LacZ) or the rGAD65 gene under the control of the CMV promoter (rAAV2-LacZ or rAAV2-CMV-GAD65), in addition to a vector in which the GAD65 gene was under the control of the JDK promoter (rAAV2-JDK-GAD65) ( Figure 1 ). The wild-type AAV2 virus is composed of the terminal repeat (TR) sequence from each end of its genome, with rep and cap genes. Each rAAV encodes transgene expression cassettes in place of rep and cap genes, including polyadenylation sequences (polyA). These viral plasmids were packaged using the AAV helper-free system, according to the method described by Hermens et al, 10 which involves iodixanol gradient ultracentrifugation for the production and purification of a high titer of rAAV virus stock. We also assessed the transduction efficiency of rAAVs expressing transgene in vitro. In our immunoblotting analysis, GAD65 protein was detected in the lysates of rAAV2-CMV-GAD65-and rAAV2-JDK-GAD65-infected Hela cells by anti-GAD65. However, no such signals were detected in the lysates of rAAV-LacZ-transduced cells (Figure 2a) . Interestingly, both rAAV2-CMV-GAD65 and rAAV2-JDK-GAD65 were infected to equal extents, but the rAAV2-JDK-GAD65 cells exhibited significantly stronger anti-GAD65 signals than did the rAAV2-CMV-GAD65 cells (Figure 2b ). In order to determine the expression of GAD65 or GABA in vitro, the Hela cells were coinfected with rAAV2s and hAD5 at 5 MOI for 48 h, then analyzed with immunocytochemistry ICC or immunofluorescence assay IFA (Figure 3) . The results of these analyses confirmed that both and rAAV2-CMV-GAD65 and rAAV2-JDK-GAD65 were able to successfully drive the production of GAD65 or GABA in vitro, while the CMV-modified JDK promoter resulted in higher levels of GAD65 expression than did the regular CMV promoter.
Behavioral recovery after intrastriatal injection of rAAV2-CMV-GAD65 or rAAV2-JDK-GAD65 in rat PD models A commonly used rat PD model, prepared by unilateral injections of 6-OHDA into the ascending nigrostriatal pathway, was used in this experiment. 11,12. At 3 weeks after the administration of 6-OHDA, all rats in all four groups (rAAV2-LacZ, n ¼ 10; rAAV2-CMV-GAD65, n ¼ 14; rAAV2-JDK-GAD65, n ¼ 14; Saline, n ¼ 10) exhibited similar degrees of impairment on both the apomorphine-induced rotation tests and the forepaw-adjusting steps tests, suggesting equivalent levels of DA depletion. These rats received rAAV (3 ml; 4.5 Â 10 4 infectious particles) injections into the STN site. At 4 weeks after the injection of rAAV vectors into the rat PD models, the rotation rates of the rAAV2-JDK-GAD65 rats had decreased by more than 60% (263.6748.3 turns/h; Po0.001), and the rotation rates of the rAAV2-CMV-GAD65 rats had decreased by more than 30% (506.3735.2 turns/h; Po0.05), as compared with the PD rats (735768.9 turns/h) ( Figure 4) . The results of the forepaw-adjusting steps tests indicated significant improvement in both the rAAV2-JDK-GAD65 rats (6.1271.26 steps; Po0.01) and the rAAV2-CMV-GAD65 rats (7.2572.6 steps; Po0.01), as compared to the PD rats (0.840.25 steps ) ( Figure 5 ).
Taken together, our results strongly suggest that the introduction of the GAD65 gene to the STN using rAAV vectors altered the physiological properties of the STNSNpr projection, and ameliorated parkinsonian symptoms in our rat animal model. Interestingly, the rAAV vector, which expressed the GAD65 gene under the Effect of transduced rAAV2-CMV-GAD65 or rAAV2-JDK-GAD65 on firing rates of basal ganglia nuclei in rat PD models
The mean firing rate and mean interspike interval were assessed for each neuron. In the normal unlesioned rats, the mean neuronal firing rates were as follows: 972. 
Expression of GAD65 gene transduced by rAAV vectors in the STN of PD rat models
We compared the distribution of transgene expression in the STN of PD rat models after the injection of 3 ml (4.5 Â 10 4 infectious particles) of rAAV2-CMV-GAD65 or rAAV2-JDK-GAD65. AT 4 weeks after injection, GAD65 transgene expression was detected in the STN by immunohistochemistry, using anti-GAD65 antibody (Figure 6a-c) . The intensity of GAD65 expression in the STN of the PD rat models injected with rAAV2-JDK-GAD65 was significantly stronger than in the rAAV2-CMV-GAD65 rats (Figure 6a and b). This indicates that GAD65 gene expression under the control of the JDK promoter is more effective than GAD65 gene expression under the control of the CMV promoter, in vivo as well as in vitro.
Discussion
Numerous advances have been made over the past several decades, using the GAD gene in clinical genetic intervention trials with PD patients. 13 PD constitutes an excellent target for gene therapy, as it is characterized by a specific neuroanatomical pathology, namely, the Effect of enhanced GAD65 expression in a rat parkinsonian model B Lee et al degeneration of dopamine neurons in the SN, with a concomitant loss of dopamine input to the striatum. This results in the accumulation of focal changes in the function of several deep brain nuclei, which have been well characterized in human and animal models, and which account for many of the motor symptoms associated with PD. Preclinical gene therapy trials, predicated on transfer of the GAD gene to the STN using an AAV vector, are currently poised to begin. 14 GAD catalyzes the production of GABA from glutamate. Two GAD isoforms have been isolated from mammalian cells: GAD65 and GAD67. 15 Both GAD isoforms require pyridoxyl-5-phosphate (PLP) as a cofactor.
16 GAD65 is principally classed as an apoenzyme, which lacks PLP, whereas GAD67 is nearly always observed as a holoenzyme coupled with PLP. GAD65 is present in a membrane-associated form in the synapses, and contributes to the production of synaptic GABA. GAD67, however, is distributed throughout the cell body, and is principally responsible for the production of cytosolic GABA. 15 Recently, Luo et al 3 presented data indicating that in a 6-OHDA lesioned rat PD model, gene therapy with GAD65, but not GAD67, led to an increase in GABA release in the SNpr following STN stimulation, as determined by microdialysis for the determination of GABA levels.
The present study explores the effectiveness of two different rAAV promoters, with regard to the expression of the GAD65 gene in the STN. As a result of the limitations inherent in the herpes simplex virus-1 and adenovirus vectors, a number of investigators have focused their attention on an alternative viral vector based on AAV. The AAV vector is one of the most attractive gene delivery vehicles for the direct introduction of therapeutic genes into the brain in the treatment of neurological diseases. Its unique characteristics are manifold: no disease is associated with the wild-type virus, the vector can infect nondividing cells, it effects long-term transgene expression with no substantial immune response, and the viral particles are physically stable. 17 In a study undertaken by Lo et al, 18 rAAVmediated CNS gene transfer resulted in sustained transgene expression for 4 months, with decreasing expression for up to 1 year. Re-expression could be activated as long as 15 months after initial injection and expression, indicating that the transgene is retained within the brain. The study of Mastakov et al 19 demonstrated that repeated administration of rAAV was efficient, induced no host immune response, and resulted in no decrease in transgene expression when the interval between injections was 3 months.
The recent characterization of other promoters, which drive a high level of sustained AAV-mediated expression in the CNS has precipitated the phasing out of the original CMV promoter. 20 Modifications of the CMV promoter have been engineered in an effort to both enhance and stabilize gene expression. 8 According to our in vitro data, the JDK promoter coupled with the GAD65 gene resulted in signal on the immunoblotting assay, which was more than 10 times as high as the signal associated with the CMV promoter (Figure 2a and b) . Figure 3 also shows that the JDK promoter produced more GAD or GABA than did the CMV promoter. This result may be attributable to the differences in promoter strength between the two viruses. The JDK promoter, a modified version of the CMV promoter, has been reported to be 10 times stronger in vivo than the regular CMV promoter. 21, 22 Our immunohistochemical data ( Figure 6 ) demonstrated that, under the control of the JDK promoter, GAD65 expression was noticeably more robust than when under the control of the CMV promoter, as expected.
In our behavioral recovery test, the JDK-driven promoter improved apomorphine-induced rotations to a greater degree than did the CMV promoter, but we detected no difference between the two promoters in the forepaw-adjusting steps test (Figures 4 and 5) . Apomorphine-induced rotational behavior is a test of druginduced behavior. It is ostensibly dependent on denervation hypersensitivity, and can be easily affected by even minor treatment-induced disruptions. However, forepaw-adjusting step tests measure spontaneous behavior, and it is difficult to assess minor changes in the dopaminergic system. This test, in fact, can only really differentiate between complete denervation and partial denervation of the dopaminergic system in hemiparkinsonian rat models. 11 Thus, the forepaw-adjusting steps test is probably not an ideal measure of differences between the JDK and CMV promoters, due primarily to the inherent limitations of the test.
It has been demonstrated in a host of studies that electrophysiological changes in basal ganglia nuclei are induced by the progressive loss of dopaminergic neurons. 12, 23, 24 According to previous studies, 6-OHDA lesioning in rat parkinsonian models induced hyperactivity of the PPN, SNpr, and STN neurons, as compared Effect of enhanced GAD65 expression in a rat parkinsonian model B Lee et al to normal control rats. 12, 25 Our present results indicate that, compared with the PD rats, the group of rats injected with the GAD65-containing JDK-driven vector exhibited more constant improvement in firing rates than did the group of the rats injected with the CMV-driven vector. This suggests that the JDK promoter induces a more effective recovery of the mean firing rates of basal ganglia nuclei (PPN, SNpr, and STN) than the CMV promoter, and thus may result in more beneficial effects with regard to the mitigation of parkinsonian symptoms.
Taken together, our results strongly suggest that the introduction of the GAD65 gene to STN using rAAV vectors resulted in alterations of the biochemical and physiological properties of the STN-SNpr projection, and alleviated Parkinson's symptoms in this rat animal model. Interestingly, the rAAV vector expressing the GAD65 gene under the control of the JDK promoter demonstrated more effective results in vitro than the CMV promoter-containing vector, even though our in vivo data did not completely support this distinction.
Materials and methods
Generation of rAAV
Recombinant AAV-2 was generated using the AAV helper-free system, obtained from Stratagene (Kirkland, WA, USA). The pAAV-LacZ vector plasmid is composed of the pAAV vector encoding a LacZ expression cassette consisting of the CMV promoter, human growth hormone intron, LacZ gene, and polyA signal. GAD65 was previously amplified by RT-PCR using rat GAD65-specific primers, subcloned into pMosblue (Pharmacia Inc., New Jersey, USA), and sequenced. pAAV-CMV-GAD65 was generated via direct ligation between linearized pAAV-MCS vector with XbaI and XhoI, and GAD65 DNA fragments digested from XbaI with XhoI. pAAV-JDK-GAD65 was generated via direct ligation between linearized pAAV-JDK vector predigested with EcoRI and GAD65 DNA fragments digested with EcoR1 from pAAV-GAD65. The pJDK plasmid was derived from the ACP plasmid, 26 by replacing the backbone containing the AMP R gene (PvuII fragment) with one containing the KanR gene (Hing II/XcmI) from the pVAX1 plasmid (Invitrogen) using blunt ligation. 21, 22 pAAV-JDK was kindly provided by Dr DK Kim, from the Samsung Hospital, in Seoul, Korea.
The 293T cells in 15 cm culture dishes, each of which contained around 1-10 Â 10 7 cells, were triple transfected via the calcium phosphate method 27 with a total of 50 mg of the pAAV vector plasmid encoding the transgene expression cassette, pAAV-RC packaging plasmid, and helper plasmid pHelper at a molar ratio of 1:1:1. After 20-24 h, the transfection medium was replaced by fresh culture medium, and the cells were incubated for another 1-2 days. The cells were harvested and pelleted, and the rAAV2 were obtained by recovering the cell lysates, following repeated dry ice-EtOH freezingthawing for the crude stock. 28 For the large preparation, the virus was collected, concentrated, and purified, according to the protocol described by Hermens et al.
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In brief, the cell pellet was resuspended in 20 ml of 10 mM Tris-HCl (pH 8.0) containing 1 mM MgCl 2 , freezethawed three times, and then treated with DNase I (10 mg/ml). After centrifugation, the supernatant was treated for ammonium sulfate precipitation. The recovered pellet, which contained rAAV, was dissolved in PBS (pH 7.4), and mixed with an equal volume of 60% iodixanol in water (Optiprep, Nycomed Pharma AS, Oslo, Norway). After 3 h of centrifugation at 71 000 r.p.m. (VII90 Beckman rotor), approximately 300 ml of fractions were collected from the bottom of Effect of enhanced GAD65 expression in a rat parkinsonian model B Lee et al the gradient. After the density of each fraction was measured, the fraction with a density of 1.39-1.45 g/ml was recovered, and dialyzed against PBS solution containing 5% glycerol. The number of total rAAV2 particles in each preparation was estimated using an ELISA kit (Progen Inc., Heigelberg, Germany). The infectious titer was defined as the average number of blue (b-gal-producing) cells per Â 100 high-power fields multiplied by factors for magnification, plate size, and dilution of the infectious stock. The total numbers of cells and blue cells were counted randomly in at least four microscopic fields of view. Infectious particles in the rAAV2-CMV-GAD65 or rAAV2-JDK-GAD65 groups were analyzed by ICC using GAD-specific antibody.
In vitro expression of rAAV vectors
In order to detect the in vitro expression of functional GAD65 production, Hela cells were coinjected with rAAV2's and hAD5 at 5 MOI. After 48 h, the cells were harvested and lysed with lysis buffer (50 mM HEPES containing 0.15 M NaCl, 0.5% Nonidet P-40, and three protease inhibitors: PMSF, TLCK, and TPCK). Precleared lysates, corresponding to 10 5 cells each, were resolved by 10% reduced sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to PVDF membrane filters (RPN 303F, Amersham, New Jersey, USA). Immunodetection was then carried out using the Pierce enhanced-chemiluminescence system (Prod#34080, Pierce) with GAD65 (1:5000, rabbit polyclonal antibody; Chemicon, CA, USA) or actin (1:5000, mouse monoclonal antibody; Sigma) primary antibody, overnight, at 41C.
In order to detect GAD65 or GABA expression by ICC or IFA, the Hela cells were coinfected with rAAV2's and hAD5 at 5 MOI for 48 h. The cells were then fixed in 4% paraformaldehyde for 30-60 min at room temperature (RT). After 3 washes with PBS and blocking for 30-60 min at RT, primary antibody specific to GAD65 (1:1000, Chemicon, CA, USA) or GABA (1:1000, Chemicon, CA, USA) was added and incubated overnight at 41C. After washing, the cells were treated with antirabbit secondary antibody for 30-50 min at RT, and the substrate DAB (3-3 0 -diaminobenzidine tetrahydrochloride, 6 mg/ml in 0.05 M Tris buffer, Sigma, MO, USA) was added for 10-20 min for ICC. For IFA, the secondary antibody conjugated with Cy-3 (1:2000, Jackson, ME, USA) was added, and the cells were incubated for another 30 min before observation under fluorescence microscopy.
Animals and surgical procedures
Every effort was made to minimize animal suffering, to reduce the number of animals used, and to utilize alternatives to in vivo techniques. The 48 male SpragueDawley rats, each weighing 230-250 g, were used in these experiments. The animals were housed in groups of five per cage, with free access to rat chow and water. The cages were kept in a temperature and humiditycontrolled room, with a 12-h light-dark cycle.
The rats were anesthetized with a mixture of ketamine (75 mg/kg), acepromazine (0.75 mg/kg) and xylazine hydrochloride (4 mg/kg). As described previously, 29 8 mg (free base weight) of 6-OHDA (Sigma, St Louis, MO, USA) in 2 ml of 0.2% ascorbic acid with 0.9% normal saline was infused, at a rate of 0.5 ml/min, into the following coordinates of the medial forebrain bundle (MFB): anterior-posterior (AP) À4.4 mm, medial-lateral (ML) 1.2 mm relative to the bregma, and dorsoventral (DV) À7.5 mm from the dura. After the 6-OHDA was injected, the cannula was left in place for 5 min before being slowly retracted. To prevent the destruction of noradrenergic neurons, desipramine (12.5 mg/kg intraperitoneally (i.p.)) was administered 30 min prior to the infusion of 6-OHDA.
PD animal models were randomly assigned to receive either rAAV2-LacZ (n ¼ 10), rAAV2-CMV-GAD65 (n ¼ 14), rAAV2-JDK-GAD65, or vehicle (n ¼ 10) injections into the STN site (3 ml; 4.5 Â 10 4 infectious particles), using the following stereotaxic coordinates: AP À3.8 mm, ML 2.5 mm, and DV 8.0 mm from the dura; according to Paxinos and Watson's Rat Brain Atlas. The vector was infused at the rate of 0.5 ml/min with a 10 ml Hamilton syringe.
Behavioral testing
Apomorphine-induced rotational behaviors were measured using automated rotameter bowls, with tethers attached to the animals' torsos. Apomorphine (0.1 mg/ kg, i.p.) was administered i.p. 3 weeks after MFB lesioning, and 4 weeks after rAAV injections. Rotational behavior was quantified every minute for 1 h after allowing the rats to habitutate for 20 min. Rats that exhibited at least five full turns per minute, contralateral to the 6-OHDA-lesioned side, were selected for subsequent experiments. The total numbers of rotations during a period of 1 h were used for analysis. Ipsilateral rotations were not included in this study. Contralateral forepaw-adjusting steps were assessed immediately before the apomorphine-induced rotational test, as described in a previous study. 11 In brief, the rats were maintained in a stationary position on the surface of the treadmill, which moved at a rate of 7.5 cm/sec. During this interval, the number of forepaw-adjusting steps involving the weight-bearing forepaw, which the rat performed to compensate for the movement of its body, was counted. Each test consisted of five trials for each forepaw, alternating between forepaws. The contralateral forepaw-adjusting steps were assessed on two occasions, 3 weeks after 6-OHDA lesioning and 4 weeks after rAAV injections.
Microelectrode recording
To obtain the extracellular single-unit recordings, the rats were anesthetized with urethane (1.3 mg/kg, i.p.). Glass micropipettes (impedance 7-10 MO at 100 Hz) filled with 2.5% pontamine sky blue in 0.5 M sodium acetate buffer (pH 7.6) were used to make the single recordings. Microelectrodes were stereotactically guided through a drilled skull burr hole to the target coordinates (PPN: À7.8 mm AP, 1.8 mm relative to the bregma ML, and DV 6.6-7.2 mm; SNpr: AP À5.3 mm, ML 2.4 mm, and DV 7.4-8.0 mm; STN: AP À3.7 mm, ML 2.5 mm, and DV 7.4-8.0 mm from the dura). Electrical signals passed through a DAM80 preamplifier (WPI, Sarasota, FL, USA) in bridge mode, and amplified signals were monitored with an oscilloscope and audio monitor. Single unit activity was isolated with a window discriminator, and firing rate data were collected on a computer running Spike 2 software (Cambridge Electronic Design, Cambridge, UK). At the end of the recording, the rats were deeply anesthetized, and the pontamine sky blue was Effect of enhanced GAD65 expression in a rat parkinsonian model B Lee et al iontophoresed at -15 mA for 20-30 min, marking the recording site. The brains were then perfused, removed, and later sectioned for histological confirmation of the recording site. The stored signal was converted to square-wave pulses with the aid of a window discriminator (WPI), and fed into an analog/digital converter and personal computer. Mean firing rates and mean interspike intervals were assessed for each neuron.
Histochemistry
In order to acquire immunohistochemical data, the rats were anesthetized and transcardially perfused with 125 ml normal saline, followed by 250 ml ice-cold 4% paraformaldehyde. The brains were removed, postfixed for 10 h, and transferred to 30% sucrose, until equilibrated. Sections were cut to a thickness of 20 mm, frozen, and immunoreacted with a primary polyclonal antibody against GAD65 (1:300; Chemicon, CA, USA) for 24 h at 41C. FITC-conjugated secondary antibody (1:1000; Santa Cruz Biotechnology Inc.) was then added to each section, and the sections were incubated for 1 h at RT in darkness.
The sections were washed with PBS, mounted on coverslips, and visualized by fluorescence microscopy. The transduction efficiency of rAAV2-LacZ was determined by X-gal histochemical staining. Sections were fixed in 0.2% glutaraldehyde and 1% paraformaldehyde at RT for 5 min, and then washed twice with PBS. The sections were immersed in a solution containing PBS (pH 7.3), 2 mM Mgcl 2 , 4 mM K 3 Fe(CN) 6 , K 4 Fe(CN) 6 , and 5-bromo-4-chloro-3-indolyl-b-D-galactoside (X-gal, 400 mg/ml) and incubated at 371C for 48 h.
Statistical analysis
Data are reported as means7s.e.m. Statistical analysis was performed using analysis of variance (electrophysiological recording data) or Kruskal-Wallis one-way analysis of variance protocols, followed by MannWhitney U-tests for the comparison of behavioral data from each group. A P-value of o0.05 was considered to be statistically significant. All statistical analyses were performed using SPSS (version 11.5; SPSS Inc., Chicago, IL, USA).
